Goodrx Holdings, Inc. (GDRX)

$7.71

-0.28

(-3.5%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $7.71
    $8.06
    $7.71
    downward going graph

    0.06%

    Downside

    Day's Volatility :4.4%

    Upside

    4.34%

    downward going graph
  • $4.14
    $9.26
    $7.71
    downward going graph

    46.37%

    Downside

    52 Weeks Volatility :55.35%

    Upside

    16.74%

    downward going graph

Returns

PeriodGoodrx Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-9.1%
5.6%
0.0%
6 Months
5.55%
5.8%
0.0%
1 Year
25.43%
17.5%
0.0%
3 Years
-80.82%
12.9%
-22.8%

Highlights

Market Capitalization
3.0B
Book Value
$1.77
Earnings Per Share (EPS)
-0.14
Wall Street Target Price
9.53
Profit Margin
-7.57%
Operating Margin TTM
9.91%
Return On Assets TTM
1.88%
Return On Equity TTM
-7.5%
Revenue TTM
775.1M
Revenue Per Share TTM
1.95
Quarterly Revenue Growth YOY
5.800000000000001%
Gross Profit TTM
701.5M
EBITDA
66.5M
Diluted Eps TTM
-0.14
Quarterly Earnings Growth YOY
-0.87
EPS Estimate Current Year
0.35
EPS Estimate Next Year
0.44
EPS Estimate Current Quarter
0.09
EPS Estimate Next Quarter
0.09

Analyst Recommendation

Buy
    57%Buy
    38%Hold
    3%Sell
Based on 26 Wall street analysts offering stock ratings for Goodrx Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
11
Hold
10
11
13
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 23.61%

Current $7.71
Target $9.53

Company Financials

FY18Y/Y Change
Revenue
249.5M
-
Net Income
43.8M
-
Net Profit Margin
17.55%
-
FY19Y/Y Change
Revenue
388.2M
↑ 55.59%
Net Income
66.0M
↑ 50.82%
Net Profit Margin
17.01%
↓ 0.54%
FY20Y/Y Change
Revenue
550.7M
↑ 41.85%
Net Income
-293.6M
↓ 544.56%
Net Profit Margin
-53.32%
↓ 70.33%
FY21Y/Y Change
Revenue
745.4M
↑ 35.36%
Net Income
-25.3M
↓ 91.4%
Net Profit Margin
-3.39%
↑ 49.93%
FY22Y/Y Change
Revenue
766.6M
↑ 2.83%
Net Income
-32.8M
↑ 29.99%
Net Profit Margin
-4.28%
↓ 0.89%
FY23Y/Y Change
Revenue
750.3M
↓ 2.12%
Net Income
-8.9M
↓ 72.99%
Net Profit Margin
-1.18%
↑ 3.1%
Q1 FY23Q/Q Change
Revenue
184.0M
↓ 0.07%
Net Income
-3.3M
↑ 66.84%
Net Profit Margin
-1.79%
↓ 0.72%
Q2 FY23Q/Q Change
Revenue
189.7M
↑ 3.09%
Net Income
58.8M
↓ 1886.81%
Net Profit Margin
30.99%
↑ 32.78%
Q3 FY23Q/Q Change
Revenue
180.0M
↓ 5.12%
Net Income
-38.5M
↓ 165.48%
Net Profit Margin
-21.39%
↓ 52.38%
Q4 FY23Q/Q Change
Revenue
196.6M
↑ 9.27%
Net Income
-25.9M
↓ 32.8%
Net Profit Margin
-13.16%
↑ 8.23%
Q1 FY24Q/Q Change
Revenue
197.9M
↑ 0.63%
Net Income
-1.0M
↓ 96.1%
Net Profit Margin
-0.51%
↑ 12.65%
Q2 FY24Q/Q Change
Revenue
200.6M
↑ 1.38%
Net Income
6.7M
↓ 763.43%
Net Profit Margin
3.34%
↑ 3.85%
FY18Y/Y Change
Total Assets
314.8M
-
Total Liabilities
1.5B
-
FY19Y/Y Change
Total Assets
386.8M
↑ 22.87%
Total Liabilities
1.5B
↓ 0.19%
FY20Y/Y Change
Total Assets
1.5B
↑ 280.07%
Total Liabilities
758.8M
↓ 48.54%
FY21Y/Y Change
Total Assets
1.6B
↑ 9.35%
Total Liabilities
775.9M
↑ 2.27%
FY22Y/Y Change
Total Assets
1.6B
↓ 0.19%
Total Liabilities
789.8M
↑ 1.79%
FY23Y/Y Change
Total Assets
1.6B
↓ 0.99%
Total Liabilities
826.8M
↑ 4.69%
Q1 FY23Q/Q Change
Total Assets
1.6B
↑ 0.43%
Total Liabilities
784.0M
↓ 0.73%
Q2 FY23Q/Q Change
Total Assets
1.7B
↑ 5.0%
Total Liabilities
796.7M
↑ 1.62%
Q3 FY23Q/Q Change
Total Assets
1.7B
↑ 0.94%
Total Liabilities
826.7M
↑ 3.76%
Q4 FY23Q/Q Change
Total Assets
1.6B
↓ 6.98%
Total Liabilities
826.8M
↑ 0.02%
Q1 FY24Q/Q Change
Total Assets
1.5B
↓ 8.49%
Total Liabilities
822.9M
↓ 0.48%
Q2 FY24Q/Q Change
Total Assets
1.5B
↑ 1.47%
Total Liabilities
806.0M
↓ 2.05%
FY18Y/Y Change
Operating Cash Flow
45.3M
-
Investing Cash Flow
-3.5M
-
Financing Cash Flow
-24.7M
-
FY19Y/Y Change
Operating Cash Flow
83.3M
↑ 84.05%
Investing Cash Flow
-37.1M
↑ 971.57%
Financing Cash Flow
-54.8M
↑ 121.48%
FY20Y/Y Change
Operating Cash Flow
131.3M
↑ 57.7%
Investing Cash Flow
-91.6M
↑ 147.25%
Financing Cash Flow
905.8M
↓ 1753.52%
FY21Y/Y Change
Operating Cash Flow
178.8M
↑ 36.12%
Investing Cash Flow
-178.7M
↑ 95.09%
Financing Cash Flow
-30.5M
↓ 103.37%
FY22Y/Y Change
Operating Cash Flow
146.8M
↓ 17.9%
Investing Cash Flow
-210.5M
↑ 17.77%
Financing Cash Flow
-120.2M
↑ 293.82%
Q1 FY23Q/Q Change
Operating Cash Flow
32.3M
↑ 1.28%
Investing Cash Flow
-14.3M
↓ 1211.04%
Financing Cash Flow
-14.1M
↑ 194.4%
Q2 FY23Q/Q Change
Operating Cash Flow
29.9M
↓ 7.5%
Investing Cash Flow
-15.0M
↑ 4.7%
Financing Cash Flow
-14.0M
↓ 0.68%

Technicals Summary

Sell

Neutral

Buy

Goodrx Holdings, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Goodrx Holdings, Inc.
Goodrx Holdings, Inc.
-8.58%
5.55%
25.43%
-80.82%
-84.18%
Solventum Corp
Solventum Corp
14.19%
-5.07%
-5.07%
-5.07%
-5.07%
Veeva Systems Inc.
Veeva Systems Inc.
16.09%
-4.12%
-3.22%
-30.48%
36.85%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
7.04%
-6.24%
30.32%
44.3%
44.3%
Healthequity Inc
Healthequity Inc
15.0%
-1.32%
14.62%
21.99%
42.92%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Goodrx Holdings, Inc.
Goodrx Holdings, Inc.
276.37
NA
NA
0.35
-0.07
0.02
NA
1.77
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
57.42
57.42
1.39
4.76
0.13
0.06
NA
32.06
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
25.3
25.3
2.2
4.24
0.21
0.06
0.0
17.08
Healthequity Inc
Healthequity Inc
68.88
68.88
1.41
2.19
0.05
0.03
NA
24.7
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Goodrx Holdings, Inc.
Goodrx Holdings, Inc.
Buy
$3.0B
-84.18%
276.37
-7.57%
Solventum Corp
Solventum Corp
Hold
$10.8B
-5.07%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$35.1B
36.85%
57.42
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$40.0B
44.3%
25.3
8.1%
Healthequity Inc
Healthequity Inc
Buy
$7.2B
42.92%
68.88
9.61%

Insights on Goodrx Holdings, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 179.95M → 200.61M (in $), with an average increase of 3.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -38.49M → 6.69M (in $), with an average increase of 875.9% per quarter

  • Vs GEHC

    In the last 1 year, Ge Healthcare Technologies Inc. has given 30.3% return, outperforming this stock by 4.9%

Institutional Holdings

  • Francisco Partners Management LP

    18.47%

  • Vanguard Group Inc

    2.14%

  • Ameriprise Financial Inc

    1.96%

  • Rubric Capital Management LP

    0.98%

  • Lakewood Capital Management, LP

    0.95%

  • SILVER LAKE GROUP, L.L.C.

    0.93%

Company Information

goodrx helps americans save on prescriptions. americans spend over $400 billion a year on prescriptions, and too many people simply can't find affordable prescriptions. even if you have insurance or medicare. we offer a website and mobile apps that gathers current prices, powerful savings tips and valuable discounts for every prescription drug at virtually every pharmacy in the us. goodrx is used by thousands of physicians and millions of americans each month. we have saved americans over $3 billion. we're not going to rest until prescriptions are affordable for all americans. we also offer goodrx for benefits, which provides technology solutions for health plans, payors and pbm's in an easy-to-understand website and mobile app experience. learn more at www.goodrx.com/benefits.

Organization
Goodrx Holdings, Inc.
Employees
694
CEO
Mr. Trevor Bezdek
Industry
Technology Services

Discover More

FAQs